Brexpiprazole for treatment-resistant major depressive disorder

References

• Kennedy SH, Lam RW, McIntyre RS, et al. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological Treatments. Can J Psychiatry. 2016;61(9):540–560.
   PubMed Web of Science ®Google Scholar
• Hamilton MJ. A Rating Scale for Depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR* D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40.
   PubMed Web of Science ®Google Scholar
• Pigott HE. The STAR* D trial: It is time to reexamine the clinical beliefs that guide the treatment of major depression. Can J Psychiatry. 2015;60(1):9–13.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011;168(7):689–701.
   PubMed Web of Science ®Google Scholar
• Johnston KM, Powell LC, Anderson IM, et al. The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature. J Affect Disord. 2018;242:195–210.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Giosuè P. Current nosology of treatment resistant depression: a controversy resistant to revision. Clin Pract Epidemiol Mental Health. 2010;6:20.
   PubMedGoogle Scholar
• McIntyre RS, Filteau M-J, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1–7.
   PubMed Web of Science ®Google Scholar
• Patkar AA, Pae C-U. Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs. 2013;27(1):29–37.
   Google Scholar
• Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980–991.
   PubMed Web of Science ®Google Scholar
• Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 2013;10(3):e1001403.
   PubMed Web of Science ®Google Scholar
• Zhou X, Keitner GI, Qin B, et al. Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis. Int J Neuropsychopharmacol. 2015;18(11):pyv060.
   PubMed Web of Science ®Google Scholar
• Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first-and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manage. 2017;13:757.
   PubMed Web of Science ®Google Scholar
• Wang HR, Woo YS, Ahn HS, et al. Can atypical antipsychotic augmentation reduce subsequent treatment failure more effectively among depressed patients with a higher degree of treatment resistance? A meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2015;18(8):pyv023.
   PubMed Web of Science ®Google Scholar
• Orsolini L, Vellante F, Valchera A, et al. Atypical antipsychotics in major depressive disorder. Understanding Depression - Volume 2. Clinical Manifestations, Diagnosis and Treatment. Springer. 2018;257–268.
   Google Scholar
• Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry. 2001;62:26–31.
   PubMed Web of Science ®Google Scholar
• MacQueen G, Santaguida P, Keshavarz H, et al. Systematic review of clinical practice guidelines for failed antidepressant treatment response in major depressive disorder, dysthymia, and subthreshold depression in adults. Can J Psychiatry. 2017;62(1):11–23.
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Vöhringer PA. The heterogeneity of depression: an old debate renewed. Acta Psychiatr Scand. 2011;124(6):497.
   PubMed Web of Science ®Google Scholar
• McAllister-Williams R, Christmas D, Cleare A, et al. Multiple-therapy-resistant major depressive disorder: a clinically important concept. Br J Psychiatry. 2018;212(5):274–278.
   PubMed Web of Science ®Google Scholar
• FDA. U.S. FDA approves otsuka and Lundbeck’s REXULTIⓇ (Brexpiprazole) as adjunctive treatment for adults with major depressive disorder. [Internet] 2015 [cited 2019 May 27]. Available from: https://www.otsuka-us.com/discover/fda-approves-otsukalundbecks-rexulti-as-adjunctive-treatment-for-adults-with-mdd-and-schizophrenia.html
   Google Scholar
• Administration USFaD. [ cited 2019 Aug 5]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
   Google Scholar
• Wang S-M, Han C, Lee S-J, et al. Second generation antipsychotics in the treatment of major depressive disorder: an update. Chonnam Med J. 2016;52(3):159–172.
   PubMedGoogle Scholar
• Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015;76(9):1224–1231.
   PubMed Web of Science ®Google Scholar
• Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015;76(9):1232–1240.
   PubMed Web of Science ®Google Scholar
• APA. Diagnostic and statistical manual of mental disorders, Fourth Edition, text revision: DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000.
   Google Scholar
• Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382–389.
   PubMed Web of Science ®Google Scholar
• Sheehan D, Harnett-Sheehan K, Raj B. The measurement of disability. Int Clin Psychopharmacol. 1996;11:89–95.
   PubMed Web of Science ®Google Scholar
• Fava M, Okame T, Matsushima Y, et al. Switching from inadequate adjunctive or combination treatment options to brexpiprazole adjunctive to antidepressant: an open-label study on the effects on depressive symptoms and cognitive and physical functioning. Int J Neuropsychopharmacol. 2017;20(1):22–30.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectr. 2016;21(1):1–6.
   PubMed Web of Science ®Google Scholar
• Orsolini L, Tomasetti C, Valchera A, et al. An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf. 2016;15(10):1329–1347.
   PubMed Web of Science ®Google Scholar
• Zohar J, Nutt DJ, Kupfer DJ, et al. A proposal for an updated neuropsychopharmacological nomenclature. Eur Neuropsychopharmacol. 2014;24(7):1005–1014.
   PubMed Web of Science ®Google Scholar
• Das S, Barnwal P, Winston AB, et al. Brexpiprazole: so far so good. Ther Adv Psychopharmacol. 2016;6(1):39–54.
   PubMed Web of Science ®Google Scholar
• Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589–604.
   PubMed Web of Science ®Google Scholar
• Durgam S, Earley W, Guo H, et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016;77(3):371–378.
   PubMed Web of Science ®Google Scholar
• Al Shirawi MI, Edgar NE, Kennedy SH. Brexpiprazole in the treatment of major depressive disorder. Clin Med Insights: Ther. 2017;9:1179559X17731801.
   Google Scholar
• Citrome L. The ABC’s of dopamine receptor partial agonists–aripiprazole, brexpiprazole and cariprazine: the 15‐min challenge to sort these agents out. Int J Clin Pract. 2015;69(11):1211–1220.
   PubMed Web of Science ®Google Scholar
• Citrome L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. J Clin Psychopharmacol. 2017;37(2):138–147.
   PubMed Web of Science ®Google Scholar
• De Berardis D, Orsolini L, Iasevoli F, et al. The novel antipsychotic cariprazine (RGH-188): state-of-the-art in the treatment of psychiatric disorders. Curr Pharm Des. 2016;22(33):5144–5162.
   PubMed Web of Science ®Google Scholar
• Hobart MZP, Skuban A, Brewer C, et al. A Long-Term, Open-Label study to evaluate the safety and tolerability of Brexpiprazole as adjunctive therapy in adults with major depressive disorder. J Clin Psychopharmacol. 2019;39: May/June. 203–209.
   PubMed Web of Science ®Google Scholar
• Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol. 2017;7(1):29–41.
   PubMed Web of Science ®Google Scholar
• Garay RP, Zarate JCA, Charpeaud T, et al. Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Rev Neurother. 2017;17(6):593–609.
   PubMed Web of Science ®Google Scholar
• Ionescu DF, Rosenbaum JF, Alpert JE. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues Clin Neurosci. 2015;17(2):111.
   PubMed Web of Science ®Google Scholar
• Gründer G, Hippius H, Carlsson A. The’atypicality’of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov. 2009;8(3):197.
   PubMed Web of Science ®Google Scholar
• Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry. 2005;7(6):268.
   PubMedGoogle Scholar
• Aftab A, Gao K. The preclinical discovery and development of brexpiprazole for the treatment of major depressive disorder. Expert Opin Drug Discov. 2017;12(10):1067–1081.
   PubMed Web of Science ®Google Scholar
• Ma M, Ren Q, Yang C, et al. Antidepressant effects of combination of brexpiprazole and fluoxetine on depression-like behavior and dendritic changes in mice after inflammation. Psychopharmacology (Berl). 2017 Feb; 234(4):525–533. doi: 10.1007/s00213-016-4483-7. Epub 2016 Nov 15.
   Google Scholar
• Ma M, Ren Q, Yang C, et al. Adjunctive treatment of brexpiprazole with fluoxetine shows a rapid antidepressant effect in social defeat stress model: role of BDNF-TrkB signaling. Sci Rep. 2016 Dec 19;6:39209. doi: 10.1038/srep39209.
   Google Scholar
• Medicine USNLo. ClinicalTrials.gov.
   Google Scholar
• Serretti A. Brexpiprazole: a step forward for precision medicine in resistant depression. Expert Opin Pharmacother. 2018;19(16):1817–1819.
   PubMed Web of Science ®Google Scholar
• Corponi F, Fabbri C, Bitter I, et al. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0924977X19302664
   PubMed Web of Science ®Google Scholar
• Krystal AD, Mittoux A, Meisels P, et al. Effects of adjunctive brexpiprazole on sleep disturbances in patients with major depressive disorder: an open-label, flexible-dose, exploratory study. Prim Care Companion CNS Disord. 2016 Sep 8;18(5). doi: 10.4088/PCC.15m01914.
   PubMedGoogle Scholar
• Björkholm C, Marcus MM, Konradsson-Geuken Å, et al. The novel antipsychotic drug brexpiprazole, alone and in combination with escitalopram, facilitates prefrontal glutamatergic transmission via a dopamine D1 receptor-dependent mechanism. Eur Neuropsychopharmacol. 2017;27(4):411–417.
   PubMed Web of Science ®Google Scholar
• Fava M, Weiller E, Zhang P, et al. Efficacy of brexpiprazole as adjunctive treatment in major depressive disorder with irritability: post hoc analysis of 2 pivotal clinical studies. J Clin Psychopharmacol. 2017;37(2):276.
   PubMed Web of Science ®Google Scholar
• Fava M, Ménard F, Davidsen CK, et al. Adjunctive brexpiprazole in patients with major depressive disorder and irritability: an exploratory study. J Clin Psychiatry. 2016;77(12):1695–1701.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Martino M, De Pasquale C, et al. The argument of antidepressant drugs in the treatment of bipolar depression: mixed evidence or mixed states? Expert Opin Pharmacother. 2012;13(14):2037–2051.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush A, Ibrahim H, et al. The inventory of depressive symptomatology, clinician rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34(1):73–82.
   PubMed Web of Science ®Google Scholar
• Berkson J. Limitations of the application of fourfold table analysis to hospital data. Biom Bull. 1946;2(3):47–53.
   Google Scholar
• Thase ME, Rush AJ. When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58 Suppl 13:23-9.
   Web of Science ®Google Scholar
• Ruhé HG, van Rooijen G, Spijker J, et al. Staging methods for treatment resistant depression. A systematic review. J Affect Disord. 2012;137(1–3):35–45.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Anastasia A, Novello S, et al. The emergence of loss of efficacy during antidepressant drug treatment for major depressive disorder: an integrative review of evidence, mechanisms, and clinical implications. Pharmacol Res. 2019 Jan;139:494–502. doi: 10.1016/j.phrs.2018.10.025. Epub 2018 Oct 29.
   Web of Science ®Google Scholar
• Fornaro M, Aguglia E, Dell’Osso L, et al. Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs? Expert Opin Pharmacother. 2011;12(18):2817–2831.
   PubMed Web of Science ®Google Scholar
• Guy W. Clinical global impression. Assess Manual Psychopharmacol. 1976;1:217–222.
   Google Scholar